Oil Prices Slide in 2025 as Oversupply and Geopolitical Risks Shape Market Outlook 
South Korea Factory Output Misses Forecasts in November Amid Ongoing Economic Uncertainty 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
China Imposes 55% Tariff on Beef Imports Above Quota to Protect Domestic Industry 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
U.S. Dollar Slides Toward Biggest Annual Loss Since 2017 as 2026 Risks Loom 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
U.S. Stock Futures Slip as Year-End Trading Turns Cautious 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Wall Street Ends Mixed as Tech and Financial Stocks Weigh on Markets Amid Thin Holiday Trading 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
LG Chem Ltd. has finally completed completes acquisition of AVEO Pharmaceuticals inc., and this was announced last week. The South Korean chemical firm is aiming to become one of the top 30 pharma companies in the world, and the acquisition is the first step to achieving the goal.
LG Chem invested around $571 million in its LG Chem Life Science Innovation Center in the United States for the takeover of the US-based firm. As per Yonhap News Agency, the deal was first announced in October 2022, and the following December, the U.S. antitrust watchdog handed its approval for the deal to go ahead.
AVEO Pharma’s board of directors proceeded to accept LG Chem's offer in the second week of January. Thus, the transaction was completed. With the completion, the American pharma firm is now listed as a second-tier subsidiary of LG Chem.
AVEO Pharmaceuticals was founded in 2002 and was listed on Nasdaq in 2010. Its sales reached KRW130 billion or about $105 million last year, and this year, it was predicted to earn KRW210 billion.
LG Chem revealed that since the company is already one of its affiliates, it will be transferring its anti-cancer drug business to AVEO. This is also a strategic move on LG Chem’s part as it is also aiming to boost its production in the U.S. Moreover, the Korean firm will be investing KRW2 trillion in the research and development (R&D) bio business by 2027 and will release at least four new drugs in markets overseas.
“The merger extends LG Chem Life Sciences’ commercial footprint to the U.S., diversifies our pipeline and advances our combined capabilities with AVEO, accelerating our ability to develop, commercialize and acquire world-class cancer therapies,” LG Chem Life Sciences president, Dr. Son Jeewoong, said in a press release. “We look forward to working closely with AVEO’s experienced and talented team as we welcome them to the LG Chem family.”
AVEO’s president and chief executive officer, Michael Bailey, added, “This transaction delivered significant value to our shareholders and AVEO is now positioned to benefit from the support and resources of LG Chem as we advance our mission of improving the lives of patients with cancer.”
